ArticleBMC infectious diseases2018
Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry.
Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Application of MALDI-TOF MS to rapid identification of anaerobic bacteria.BMC infectious diseases · 2019Pooled it
- Accuracy of matrix-assisted LASER desorption ionization-time of flight mass spectrometry for identification of Candida.Bioscience reports · 2019Pooled it
- Article
- Characterization and virulence of yeasts associated with neonatal thrush.BMC microbiology · 2025Article
- A Review of Case Reports of Rare Clinical Yeast Infections in the Last Five Years.Mycopathologia · 2025Review
- Genital-oral transmission ofInternational journal of STD & AIDS · 2025Article
- Antifungal susceptibility profile of Candida species and uncommon yeasts from drug abusers with oral candidiasis.BMC oral health · 2024Article
- What are the 100 most cited fungal genera?Studies in mycology · 2024Article
- Prevalence and drug susceptibility of clinicalOne health (Amsterdam, Netherlands) · 2024Article
- Exploring the diversity of uncommon oral yeast species and associated risk factors among substance abusers in southwestern Iran.Scientific reports · 2024Article
- Mechanisms and Potential Clinical Implications of Oral Microbiome in Oral Squamous Cell Carcinoma.Current oncology (Toronto, Ont.) · 2023Review
- Article
- Influence of Bariatric Surgery on Oral Microbiota: A Systematic Review.European journal of dentistry · 2023Article
- Catheter-associated blood stream infections due to Candida pararugosa in a patient with acute myeloid leukemia: A case report.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Antifungal Resistance of ClinicalIranian journal of public health · 2023Review
- Advances in the Application of the Non-Conventional YeastJournal of fungi (Basel, Switzerland) · 2023Review
- MetaFunc: taxonomic and functional analyses of high throughput sequencing for microbiomes.Gut microbiome (Cambridge, England) · 2023Article
- A Comprehensive Review of Identification Methods for Pathogenic Yeasts: Challenges and Approaches.Advanced biomedical research · 2023Review
- A 3-year study ofFrontiers in cellular and infection microbiology · 2023Article
- Phenotype, genotype, and mating type determination in oral Candida albicans isolates from pediatric patients with neutropenia.Journal of clinical laboratory analysis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundOpportunistic infections due to Candida species occur frequently in cancer patients because of their inherent immunosuppression. The aim of the present study was to investigate the epidemiology of yeast species from the oral cavity of patients during treatment for oncological and haematological malignancies.
methodsMALDI-TOF was performed to identify yeasts isolated from the oral cavity of 350 cancer patients. Moreover, antifungal susceptibility testing was performed in according to CLSI guidelines (M27-A3).
resultsAmong 162 yeasts and yeast-like fungi isolated from the oral cavity of cancer patients, Candida albicans was the most common species (50.6%), followed by Candida glabrata (24.7%), Pichia kudriavzevii (Candida krusei (9.9%)), Candida tropicalis (4.3%), Candida dubliniensis (3.7%), Kluyveromyces marxianus (Candida kefyr (3.7%)) and Candida parapsilosis (1%). In addition, uncommon yeast species i.e., Saprochaete capitata, Saccharomyces cerevisiae, Clavispora lusitaniae (C. lusitaniae) and Pichia kluyveri (C. eremophila) were recovered from oral lesions. Oral colonization by C. albicans, non-albicans Candida species and uncommon yeasts were as follow; 55%, 44% and 1%, whereas oral infection due to C. albicans was 33.3%, non-albicans Candida species 60.6%, and uncommon yeasts 6.1%. Poor oral hygiene and xerostomia were identified as independent risk factors associated with oral yeast colonization. The overall resistance to fluconazole was 11.7% (19/162). Low MIC values were observed for anidulafungin for all Candida and uncommon yeast species.
conclusionsThis current study provides insight into the prevalence and susceptibility profiles of Candida species, including emerging Candida species and uncommon yeasts, isolated from the oral cavity of Iranian cancer patients. The incidence of oral candidiasis was higher amongst patients with hematological malignancies. The majority of oral infections were caused by non-albicans Candida species which were often more resistant to anti-fungal agents. Our findings suggest that anidulafungin should be used as antifungal of choice for prophylaxis in clinically high-risk patients with documented oral colonization or infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.